Waters (WAT) Q3 FY25 earnings call

Waters Corporation delivered strong Q3 FY25 results, driven by robust instrument replacement cycles, successful new product introductions like Xevo CDMS, and strategic expansion into high-growth areas such as GLP-1 and bioseparations. The company is well-positioned for continued momentum into FY26, reinforced by a stable policy environment and the pending combination with BD's Biosciences & Diagnostic Solutions business, which is expected to unlock significant synergies and long-term value.